More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
A world-leading researcher in solid electrolytes and sophisticated electron microscopy methods received Oak Ridge National Laboratory’s top science honor today for her work in developing new materials for batteries. The announcement was made during a livestreamed Director’s Awards event hosted by ORNL Director Thomas Zacharia.
Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.
The U.S. Department of Energy’s Office of Science announced allocations of supercomputer access to 51 high-impact computational science projects for 2022 through its Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program.
A team including researchers from the Department of Energy’s Oak Ridge National Laboratory has developed a digital tool to better monitor a condition known as Barrett’s esophagus, which affects more than 3 million people in the United States.
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
Sergei Kalinin, a scientist and inventor at the Department of Energy’s Oak Ridge National Laboratory, has been elected a fellow of the Microscopy Society of America professional society.
The U.S. Department of Energy’s Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program is seeking proposals for high-impact, computationally intensive research campaigns in a broad array of science, engineering and computer science domains.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.